Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer
N. Lynn Henry(University of Michigan), David A. Flockhart(Indiana University – Purdue University Indianapolis), Janet S. Carpenter(Indiana University – Purdue University Indianapolis), Jessica Dantzer(University School), Anne Nguyen(Indiana University School of Medicine), James M. Rae(University of Michigan), Anna Maria Storniolo(Indiana University Health), Vered Stearns(Johns Hopkins University), Steffi Oesterreich(University of Pittsburgh), Christina L. Gersch(University of Michigan), Daniel F. Hayes(University of Michigan–Ann Arbor), Santosh Philips(Indiana University School of Medicine), Zeruesenay Desta(Indiana University School of Medicine), Lang Li(Nanjing Agricultural University), Kelley M. Kidwell(University of Michigan), Todd C. Skaar(Indiana University School of Medicine)
Cited by 64
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k